Proteomics Market Size, Growth, Share & Trends Analysis
Proteomics Market by Instrumentation (Mass Spectrometry, HPLC, Electrophoresis, Protein Microarray), Reagents, Services (Core, Bioinformatics), Software, Workflow (Sample Prep, Separation), Applications, End User, Competition - Global Forecast to 2031
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The proteomics market is projected to reach USD 67.55 billion by 2031 from USD 39.84 billion in 2026, at a CAGR of 11.1% from 2026 to 2031. The growth of the proteomics market is driven by the increasing adoption of advanced mass spectrometry and immunoassay technologies, along with rising demand for biomarker discovery, translational research, and precision medicine applications. Expanding use of proteomics in disease profiling, clinical diagnostics, and drug discovery is accelerating the adoption of protein analysis workflows across research and healthcare settings. Additionally, the growing focus on understanding protein expression, post-translational modifications, and disease mechanisms is boosting demand for advanced analytical platforms, reagents, software, and proteomics services across the market.
KEY TAKEAWAYS
-
By RegionNorth America is expected to grow at a CAGR of 11.2% till 2031. The growth in this region is driven by strong proteomics research activities, advanced healthcare and research infrastructure, high investments in biotechnology and pharmaceutical R&D, supportive regulatory frameworks, and the presence of leading market players promoting the adoption of advanced protein analysis technologies.
-
By Reagent & ConsumableThe immunoassay reagents & consumables segment accounted for the largest share of the proteomics market in 2025. This growth is driven by the frequent and recurring use of immunoassay reagents & consumables across protein detection, biomarker validation, and clinical testing workflows, ensuring consistent demand across research and diagnostic settings.
-
By ApplicationBy application, the clinical diagnostics segment is expected to grow at a 11.3% CAGR. This is attributed to the increasing use of proteomics in disease diagnosis, biomarker-based testing, patient stratification, and treatment monitoring, particularly across oncology, infectious diseases, and neurological disorders.
-
By ServiceBy service, core proteomics services are projected to grow at the highest CAGR of 11.6%, driven by outsourcing of LC-MS/MS workflows, biomarker discovery, target validation, biologics characterization, and demand for specialized proteomics expertise.
-
Competitive LandscapeThermo Fisher Scientific Inc., Agilent Technologies, Inc., Merck KGaA were identified as some of the star players in the proteomics market, given their strong market share and product footprint.
-
Competitive LandscapeCreative Proteomics, HORIBA, Ltd., LabVantage - Biomax GmbH, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The proteomics market is growing due to the increasing adoption of advanced mass spectrometry and immunoassay technologies, rising focus on precision medicine and biomarker research, expanding use of proteomics in clinical diagnostics and drug discovery, and continuous advancements in high-throughput protein analysis and proteomics data interpretation.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The proteomics market is shifting from conventional protein analysis methods toward advanced high-throughput mass spectrometry, AI-enabled proteomics informatics, and integrated multi-omics platforms for deeper biological and clinical insights. Adoption of single-cell and spatial proteomics technologies is increasing, enabling high-resolution analysis of protein expression across individual cells and tissue microenvironments. Additionally, the growing demand for faster, scalable, and low-input proteomics workflows supported by automation, cloud-based data management, and improved bioinformatics tools is accelerating market growth. Furthermore, enhanced protein biomarker discovery, improved quantification and functional analysis, reduced turnaround time for protein analysis, and broader standardization of clinical proteomics workflows are driving advances in this market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Advancements in DIA and high-throughput mass spectrometry
-
Growing clinical and plasma proteomics adoption for biomarker discovery and translational diagnostics
Level
-
High capital intensity of high-resolution mass spectrometry platforms
-
Complexity of proteomics data analysis
Level
-
Emergence of single-cell proteomics for high-resolution cellular profiling
-
Expansion of spatial proteomics in tissue-context biology and biomarker research
Level
-
Limited detection of low-abundance proteins
-
Lack of standardization across workflows
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Advancements in DIA and high-throughput mass spectrometry
Advancements in data-independent acquisition (DIA) and high-throughput mass spectrometry are significantly strengthening the proteomics market by improving analytical depth, reproducibility, and processing speed. These technologies enable broader protein coverage across large sample cohorts, making proteomics more suitable for biomarker discovery, translational research, and clinical applications. Improved sensitivity, faster scan rates, and better quantification capabilities are also helping researchers generate more reliable protein-level insights across complex biological samples.
Restraint: High capital intensity of high-resolution mass spectrometry platforms
The high capital intensity of high-resolution mass spectrometry platforms remains a major restraint for the proteomics market. Advanced instruments require substantial upfront investment and are often accompanied by high maintenance, calibration, software, and infrastructure costs. In addition, laboratories need skilled personnel to operate these systems and interpret complex results, which further increases the total cost of ownership. This creates adoption barriers for small and mid-sized laboratories, research institutes, and emerging biotechnology companies.
Opportunity: Emergence of single-cell proteomics for high-resolution cellular profiling
The emergence of single-cell proteomics presents a strong growth opportunity for the proteomics market by enabling protein-level analysis at the resolution of individual cells. This is particularly important in areas such as oncology, immunology, neuroscience, and stem cell research, where cellular heterogeneity plays a critical role in disease progression and treatment response. Unlike bulk proteomics, single-cell proteomics can reveal rare cell populations and functional differences that may otherwise remain undetected.
Challenge: Limited detection of low-abundance proteins
Limited detection of low-abundance proteins remains a key challenge in the proteomics market, especially in complex sample types such as plasma, serum, and tissue lysates. Many biologically important proteins, including signaling molecules and disease-associated biomarkers, are present at very low concentrations and are often masked by highly abundant proteins. This reduces analytical sensitivity and makes consistent detection difficult in discovery workflows.
PROTEOMICS MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
SomaScan proteomics platform applied in clinical trials to analyze proteomic biomarkers across multiple therapeutic areas and support translational medicine research | Proteomic biomarker identification | Improved translational insights | Better patient stratification | Enhanced clinical trial decision-making |
 |
Olink Explore platform applied in a large-scale human proteome study to measure thousands of proteins across population-scale samples and support disease research and biomarker discovery | Large-scale biomarker discovery | Improved disease prediction research | Support for drug target identification | Acceleration of precision medicine research |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The proteomics market ecosystem comprises product providers (Illumina, Revvity, Agilent Technologies, Thermo Fisher Scientific), service providers (Fios Genomics, Creative Proteomics, MedGenome, Macrogen), regulatory authorities (US FDA, CDSCO, OLAW, MHRA, ANVISA, Health Canada), and end users (Amgen, Novartis, Merck, MIT). Product providers supply instruments, reagents, consumables, and software used across protein identification, quantification, biomarker discovery, and proteomic profiling workflows. Service providers support the market through proteomics testing, bioinformatics, data interpretation, and specialized analytical services. Regulatory authorities establish requirements for quality, safety, validation, and compliance in research and clinical settings. End users, including biopharmaceutical companies and research institutes, utilize these solutions for biomarker discovery, translational research, disease profiling, drug development, and clinical proteomics applications.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Proteomics Market, By Service
In 2025, the core proteomics services segment dominated the proteomics market. This leadership is driven by the increasing outsourcing of protein identification, quantification, biomarker discovery, and mass spectrometry-based analysis across pharmaceutical, biotechnology, and academic research workflows. The need for specialized analytical expertise, advanced instrumentation access, and high-quality reproducible results continues to support steady demand for core proteomics services.
Proteomics Market, By Application
In 2025, clinical diagnostics dominated the proteomics market, supported by the growing use of protein biomarkers in disease diagnosis, patient stratification, prognosis assessment, and treatment monitoring. Proteomics technologies play a critical role in identifying clinically relevant protein signatures and supporting precision medicine approaches across oncology, neurological disorders, infectious diseases, and other disease areas.
Proteomics Market, By End User
In 2025, biopharmaceutical companies dominated the proteomics market due to their strong focus on R&D and increasing investments in biomarker-driven drug discovery, translational research, and precision medicine. These organizations widely utilize proteomics technologies to support target identification, mechanism-of-action studies, clinical research, and biomarker validation, thereby driving demand across the market.
PROTEOMICS MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS: COMPANY EVALUATION MATRIX
In the proteomics market company evaluation matrix, Thermo Fisher Scientific Inc. is positioned as a star player due to its strong presence across proteomics workflows. The company offers a broad range of instruments, reagents, consumables, software, and integrated solutions used in mass spectrometry-based proteomics, protein analysis, biomarker discovery, and translational research applications. Its global reach, comprehensive portfolio, strong installed base, and consistent focus on workflow integration make it a preferred partner for pharmaceutical, biotechnology, academic, and clinical research organizations. Bruker is considered an emerging leader in this market. The company is strengthening its position through advanced mass spectrometry platforms, innovations in high-sensitivity and high-throughput proteomics, and growing capabilities in areas such as single-cell proteomics, spatial proteomics, and multi-omics workflows. Its continued product innovation and expanding application focus are supporting increased adoption across research and translational settings, thereby strengthening its market position.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific Inc. (US)
- Agilent Technologies, Inc. (US)
- Merck KGaA (Germany)
- Danaher Corporation (US)
- Shimadzu Corporation (Japan)
- Waters Corporation (US)
- Bio-Rad Laboratories, Inc. (US)
- Bruker (US)
- Revvity (US)
- Illumina, Inc. (US)
- Promega Corporation (US)
- Eurofins Scientific (Luxembourg)
- QIAGEN (Netherlands)
- Charles River Laboratories (US)
- ProtaGene (Germany)
- Bio-Techne (US)
- Azenta US Inc. (US)
- Quanterix (US)
- Proteomics International (Australia)
- Hamilton Company (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 36.48 Billion |
| Market Forecast in 2031 (Value) | USD 67.55 Billion |
| Growth Rate | CAGR of 11.1% from 2026-2031 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
WHAT IS IN IT FOR YOU: PROTEOMICS MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown | Country-level market sizing and growth forecasts (Sweden, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) | Provides granular country-level insights, enabling clients to prioritize high-growth markets |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, and detect market gaps for smarter collaboration, outsourcing, and strategic market entry decisions |
RECENT DEVELOPMENTS
- April 2026 : Thermo Fisher entered a strategic collaboration with PRECISE to advance population-scale proteomics. Under the program, the company deployed an integrated proteomics strategy combining Olink Proximity Extension Assay platforms with the Orbitrap Astral mass spectrometry system, supporting precision medicine and longitudinal cohort research.
- April 2026 : Agilent collaborated with OmixAI to expand AI-driven proteomics in South Korea. Under the three-year strategic collaboration, the companies combined Agilent’s Bravo Automated Liquid Handling Platform with OmixAI’s multimodal database and AI-enabled experimentation capabilities to support automated sample preparation, biomarker discovery, targeted protein degradation research, and high-throughput protein profiling for translational research and precision medicine.
- April 2026 : Revvity launched Signals BioDesign, a cloud-native molecular cloning solution for biologics research workflows. The platform supported construct design, primer design, sequencing analysis, and protein translation.
- January 2026 : Illumina completed the acquisition of SomaLogic. The company stated that the combination expanded its leadership in proteomics and multiomics by pairing SomaLogic’s SomaScan platform with Illumina’s NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics platform.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global proteomics market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the proteomics market. The secondary sources used for this study include Centre for Drug Evaluation and Research, European Proteomics Association (EuPA), European Medicines Agency (EMA), European Bioinformatics Institute (EMBL-EBI), French Society for Electrophoresis and Proteomics Analysis (SFEAP), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Food and Drug Administration (FDA), Biotechnology and Biological Sciences Research Council (BBSRC), Pharmaceutical Research and Manufacturers of America (PhRMA), United Kingdom’s Research and Innovation’s (UKRI), World Journal of Pharmaceutical Sciences (WJPS), National Institutes of Health, and National Center for Biotechnology Information (NCBI). Academic Journals and Company Websites, corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, among others. Secondary data were collected and analyzed to determine the overall size of the global proteomics market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the proteomics market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Proteomics involves the comprehensive evaluation of the structure and function of proteins to understand an organism's nature. It systematically identifies and characterizes proteins, including their sequences, abundances, post-translational modifications, interactions, activities, subcellular localizations, and structures.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Life science companies
- Academic & research institutes
- Private research institutes
- Venture capitalists & investors
- Clinical laboratories and diagnostic laboratories
- Biobanks and translational research centers
- Market research & consulting firms
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the proteomics market based on offering, instrumentation technology, reagents & consumables, type, service, software, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall proteomics market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the proteomics market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the proteomics market
- To benchmark players within the proteomics market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
- Further breakdown of the Rest of Europe Proteomics Market, by country
- Further breakdown of the Rest of Asia Pacific Proteomics Market, by country
- Further breakdown of the Rest of Latin America Proteomics Market, by country
- Further breakdown of the Rest of Middle East Proteomics Market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Proteomics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Proteomics Market
Still Researching the
Proteomics Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
Caleb
Apr, 2026
We are working in multi-omics research. How is demand evolving for integrated proteomics and metabolomics platforms?.
Noah
Apr, 2026
How is AI transforming proteomics and bioinformatics to accelerate drug discovery and life sciences research?.
Bentley
Apr, 2026
How is AI accelerating omics research and supporting advancements in precision medicine and biological data analysis?.
Bennett
Apr, 2026
How is AI being used in proteomics workflows for early-stage monoclonal antibody characterization and sample preparation?.
Maxwell
Apr, 2026
How is proteomics-based diagnostic laboratory testing evolving with advancements in AI and high-throughput technologies?.
Evan
Apr, 2026
How are genomics, proteomics, and metabolomics collectively advancing virology research and biochemical understanding?.
Luke
Apr, 2026
What are the fastest-growing segments in proteomics, and how is market demand evolving across diagnostics and drug discovery applications?.
Derek
Apr, 2026
How are proteomics and metabolomics contributing to precision medicine and advanced disease understanding?.
Jason
Apr, 2026
How are proteomics diagnostic laboratories evolving with advanced technologies and AI-driven workflows?.
Kyle
Apr, 2026
How is food microbiology research benefiting from proteomics and advanced analytical techniques?.
Emma
Apr, 2026
What are the key adoption challenges limiting the broader use of proteomics in clinical and translational research?.
Daniel
Apr, 2026
How scalable are proteomics technologies for large-scale population studies or precision medicine initiatives?.
Chloe
Apr, 2026
How do you see the integration of proteomics data with other omics technologies shaping future healthcare models?.
Mason
Apr, 2026
Where do you see the biggest commercial opportunities in the proteomics market over the next decade?.
Gary
Mar, 2022
Looking to gain more insights on the global Proteomics Market.
Nicholas
Mar, 2022
What are the growth opportunities in Proteomics Market?.
Eric
Mar, 2022
Can you enlighten us on geographical growth analysis in Proteomics Market?.